AGN-201904

CAS No. 651729-53-2

AGN-201904( —— )

Catalog No. M33962 CAS No. 651729-53-2

AGN-201904 is an omeprazole prodrug and proton pump inhibitor, which may delay aging and be used for the prevention and treatment of peptic ulcers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AGN-201904
  • Note
    Research use only, not for human use.
  • Brief Description
    AGN-201904 is an omeprazole prodrug and proton pump inhibitor, which may delay aging and be used for the prevention and treatment of peptic ulcers.
  • Description
    AGN-201904 is an omeprazole prodrug and proton pump inhibitor, which may delay aging and be used for the prevention and treatment of peptic ulcers.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    ATPase
  • Recptor
    ATPase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    651729-53-2
  • Formula Weight
    559.61
  • Molecular Formula
    C25H25N3O8S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(O)COC1=CC=C(C=C1)S(=O)(=O)N2C(=NC=3C=C(OC)C=CC32)S(=O)CC4=NC=C(C(OC)=C4C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Digoxin

    Digoxin is occasionally used in the treatment of various heart conditions namely atrial fibrillation atrial flutter and sometimes heart failure that cannot be controlled by other medication.

  • (-)-Denudatin B

    (-)-Denudatin B is derived from Magnolia fargesii. (-)-Denudatin B has nonspecific antiplatelet action at high concentration by inhibiting phosphoinositides breakdown induced by collagen and thrombin.

  • BHQ

    BHQ is an effective and selective endoplasmic reticulum Ca2+-ATPase inhibitor.